Quantum BioPharma Advances Lucid-MS to Phase 2
Analysis based on 8 articles · First reported Jun 08, 2026 · Last updated Jun 25, 2026
The advancement of Lucid-MS by Quantum BioPharma into phase 2 clinical trials, following a successful phase 1 and IND submission to the United States — Food and Drug Administration, is a positive development for the biotechnology and pharmaceutical markets. This progress suggests potential for a novel treatment for multiple sclerosis, which could lead to increased investor interest in Quantum BioPharma and other companies pursuing neurodegenerative disease therapies.
Quantum BioPharma Ltd. is advancing Lucid-MS, a patented, first-in-class drug candidate for multiple sclerosis, into phase 2 clinical trials. The company recently completed phase 1 clinical studies, which demonstrated a favorable safety profile, and submitted an Investigational New Drug application to the United States — Food and Drug Administration in April 2026. Lucid-MS is designed to directly target the myelin sheath, aiming to prevent and reverse myelin degradation, an underlying mechanism of multiple sclerosis. This approach differentiates it from existing therapies that primarily focus on immune suppression. Quantum BioPharma has also partnered with Allucent to support the execution of the planned phase 2 trial. This development represents a significant step in addressing the unmet medical need for therapies that can halt the progression of multiple sclerosis.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard